For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Budget 2024: Why does primary care miss out on major funding?
Budget 2024: Why does primary care miss out on major funding?

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 19 June.
From Barbara: Budget is always a big deal here in the newsroom. We are eternally optimistic, but likewise eternally disappointed. It’s been a few years since we could write a cracker yarn about a significant increase in primary care funding. This year was no different. Our regular policy puzzler (and Auckland university professor of health systems) Tim Tenbensel explains the problem at hand when it comes to attracting Budget money to primary care
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.